Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as the first medical device company to do so in 2024 and the first under the new fifth set of standards for the board [2][12]. Company Overview - Established in 2015, Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform clinical practices [6][10]. - The company has launched 11 products and has 6 more in development, covering various categories including IVUS systems and FFR systems [6]. Product Highlights - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [7]. - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations in multiple domestic and international guidelines [7]. - Beixin Life's PFA system is the first in China to be included in breakthrough clinical research at the European Society of Cardiology [8]. Market Impact - The successful launch of Beixin Life's products has filled a significant gap in the domestic market, previously reliant on imported products for precise cardiovascular diagnosis [7][10]. - The company has established a presence in over 30 provinces in China and has clinical applications in more than 1,000 hospitals globally, including in Belgium, Germany, and Italy [8]. Innovation and R&D - Beixin Life emphasizes long-term independent research and technological innovation, having developed four core technology platforms for medical devices [10]. - The company holds 185 domestic and international patents, including 86 invention patents and 14 PCT international patent applications [10]. Future Prospects - The listing is seen as a new starting point for Beixin Life, enabling it to accelerate development in innovation, global market expansion, and capital collaboration [12]. - The cardiovascular intervention field is expected to see significant growth, driven by increasing clinical needs and technological advancements [11]. Investment and Support - Major institutional investors include Sequoia China and Qiming Venture Partners, who have expressed confidence in Beixin Life's innovative capabilities and market potential [14][15]. - The company has received continuous support from its investors, focusing on building a strong product portfolio and enhancing its competitive edge in the market [15][17].
北芯生命正式登陆科创板：开盘上涨超200%，第五套标准重启后迎首个医疗器械IPO